You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVincristine
Accession NumberDB00541  (APRD00495)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionVincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
Structure
Thumb
Synonyms
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
Leurocristine
Vincristin
Vincristina
Vincristinum
External Identifiers
  • L 37231
  • NSC 67574
  • VCR
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MarqibokitTalon Therapeutics, Inc2013-01-14Not applicableUs
Oncovin Solution 1mg/mlliquid1 mgintravenousEli Lilly Canada Inc1984-12-311998-08-04Canada
Vincristine Sulfate Inj 1mg/ml USPliquid1 mgintravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311999-08-10Canada
Vincristine Sulfate Inj 5mg/vial USPpowder for solution5 mgintravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311996-09-10Canada
Vincristine Sulfate Injectionsolution1 mgintravenousTeva Canada Limited1995-12-31Not applicableCanada
Vincristine Sulfate Injectionsolution1 mgintravenousAccord Healthcare IncNot applicableNot applicableCanada
Vincristine Sulfate Injection USPsolution1 mgintravenousUman Pharma IncNot applicableNot applicableCanada
Vincristine Sulfate Injection USPsolution1 mgintravenousHospira Healthcare Corporation1997-08-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vincasar PFSinjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
Vincasar PFSinjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
Vincristine Sulfateinjection, solution1 mg/mLintravenousHospira Worldwide, Inc.1988-04-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlcavixinKorea United Pharma
AlcristAlkem
CitomidCSC
CytocristinCipla
OncocristinSun
OncovinLilly
OncrivinTeva
SindovinActavis
TevacristinTeva
VincesIvax
VincrisinTeva
VincristinGedeon Richter
VincrisulSTADA
VinlonCelon
VinracineMeizler
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vincristine Sulfate
Thumb
  • InChI Key: AQTQHPDCURKLKT-VEGNXYBXSA-N
  • Monoisotopic Mass: 922.367023274
  • Average Mass: 923.036
DBSALT000314
Categories
UNII5J49Q6B70F
CAS number57-22-7
WeightAverage: 824.9576
Monoisotopic: 824.399644032
Chemical FormulaC46H56N4O10
InChI KeyInChIKey=OGWKCGZFUXNPDA-XQKSVPLYSA-N
InChI
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([[email protected]](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassVinca alkaloids
Sub ClassNot Available
Direct ParentVinca alkaloids
Alternative Parents
Substituents
  • Vinca alkaloid skeleton
  • Carbazole
  • Indole or derivatives
  • Indole
  • Anisole
  • Aralkylamine
  • Tetrahydropyridine
  • Alkyl aryl ether
  • Benzenoid
  • N-alkylpyrrolidine
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Acetate salt
  • Methyl ester
  • Tertiary carboxylic acid amide
  • Tertiary alcohol
  • Pyrrolidine
  • Pyrrole
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
PharmacodynamicsVincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Mechanism of actionThe antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Related Articles
AbsorptionNot Available
Volume of distribution

Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.

Protein binding~75%
Metabolism

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine.

Route of eliminationThe liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine.
Half lifeWhen intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.
ClearanceNot Available
ToxicityIVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg. Marqibo® must only be administered IV because it is fatal if administered by other routes. Marqibo® also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically significant adverse effect of vincristine is neurotoxicity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Vincristine Action PathwayDrug actionSMP00437
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9738
Blood Brain Barrier-0.9514
Caco-2 permeable+0.6262
P-glycoprotein substrateSubstrate0.9027
P-glycoprotein inhibitor IInhibitor0.6573
P-glycoprotein inhibitor IIInhibitor0.6919
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8071
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7666
CYP450 1A2 substrateNon-inhibitor0.9203
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7491
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8574
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8938
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9324 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9699
hERG inhibition (predictor II)Inhibitor0.5265
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Teva parenteral medicines inc
  • Bristol myers squibb
  • Abic ltd
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Kit
Liquidintravenous1 mg
Injection, solutionintravenous1 mg/mL
Powder for solutionintravenous5 mg
Solutionintravenous1 mg
Prices
Unit descriptionCostUnit
Vincristine 2 mg/2 ml vial18.06USD ml
Oncovite tablet0.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723338 No2000-03-312020-03-31Us
US7247316 No2000-09-252020-09-25Us
US7887836 No2000-03-312020-03-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220 °CPhysProp
logP2.82HANSCH,C ET AL. (1995)
pKa5MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.03 mg/mLALOGPS
logP3.36ALOGPS
logP3.13ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)10.85ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area171.17 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity221.48 m3·mol-1ChemAxon
Polarizability88.59 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Homer L. Pearce, “Method of preparing vincristine.” U.S. Patent US4303584, issued November, 1967.

US4303584
General References
  1. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62. [PubMed:8608515 ]
  2. Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3. [PubMed:17355029 ]
  3. JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427. [PubMed:14070392 ]
  4. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. [PubMed:10226730 ]
External Links
ATC CodesL01CA02
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (362 KB)
MSDSDownload (90.9 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Vincristine.
AcetaminophenThe serum concentration of Vincristine can be increased when it is combined with Acetaminophen.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Vincristine.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vincristine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Vincristine.
AfatinibThe serum concentration of Vincristine can be increased when it is combined with Afatinib.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Vincristine.
AlbendazoleThe serum concentration of Vincristine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Vincristine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Vincristine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Vincristine can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Vincristine.
AmantadineThe serum concentration of Vincristine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Vincristine.
Aminohippuric acidThe serum concentration of Vincristine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Vincristine can be increased when it is combined with Amitriptyline.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Vincristine.
AmlodipineThe serum concentration of Vincristine can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Vincristine can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Vincristine can be increased when it is combined with Amsacrine.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Vincristine.
AprepitantThe serum concentration of Vincristine can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.
AstemizoleThe serum concentration of Vincristine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Vincristine can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Vincristine.
AtenololThe serum concentration of Vincristine can be increased when it is combined with Atenolol.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Vincristine.
AtomoxetineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Vincristine can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Vincristine.
AzelastineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Vincristine can be increased when it is combined with Azithromycin.
BenzocaineThe serum concentration of Vincristine can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Vincristine can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Vincristine.
BevacizumabBevacizumab may increase the cardiotoxic activities of Vincristine.
BexaroteneThe serum concentration of Vincristine can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Vincristine can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Vincristine can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Vincristine.
BortezomibThe metabolism of Vincristine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Vincristine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vincristine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vincristine.
BromocriptineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.
BuprenorphineThe serum concentration of Vincristine can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Vincristine can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Vincristine.
CaffeineThe serum concentration of Vincristine can be increased when it is combined with Caffeine.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Vincristine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Vincristine.
CanagliflozinThe serum concentration of Vincristine can be increased when it is combined with Canagliflozin.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Vincristine.
CandesartanThe serum concentration of Vincristine can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Vincristine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Vincristine can be increased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Vincristine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Vincristine.
CarvedilolThe serum concentration of Vincristine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Vincristine can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Vincristine can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Vincristine.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Vincristine.
ChloroquineThe serum concentration of Vincristine can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vincristine.
ChlorpropamideThe serum concentration of Vincristine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Vincristine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Vincristine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Vincristine can be increased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Vincristine.
CiprofloxacinThe serum concentration of Vincristine can be increased when it is combined with Ciprofloxacin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Vincristine.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Vincristine.
CitalopramThe serum concentration of Vincristine can be increased when it is combined with Citalopram.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Vincristine.
ClarithromycinThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Vincristine.
ClemastineThe metabolism of Vincristine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Vincristine.
ClofazimineThe serum concentration of Vincristine can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Vincristine.
ClomipramineThe serum concentration of Vincristine can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Vincristine.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Vincristine.
ClotrimazoleThe serum concentration of Vincristine can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Vincristine.
CobicistatThe serum concentration of Vincristine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Vincristine.
ColchicineThe serum concentration of Vincristine can be increased when it is combined with Colchicine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Vincristine.
ColforsinThe serum concentration of Vincristine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Vincristine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Vincristine.
CrizotinibThe serum concentration of Vincristine can be increased when it is combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Vincristine.
CyclophosphamideThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Vincristine can be increased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Vincristine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.
DabrafenibThe serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Vincristine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Vincristine can be increased when it is combined with Dactinomycin.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Vincristine.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Vincristine.
DarunavirThe serum concentration of Vincristine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Vincristine.
DaunorubicinThe serum concentration of Vincristine can be increased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Vincristine.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Vincristine.
DeferasiroxThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Vincristine can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.
DesipramineThe serum concentration of Vincristine can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vincristine.
DesloratadineThe serum concentration of Vincristine can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Vincristine can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Vincristine.
DiclofenacThe serum concentration of Vincristine can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vincristine.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vincristine.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Vincristine.
DigoxinThe serum concentration of Vincristine can be increased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Vincristine.
DihydroergotamineThe serum concentration of Vincristine can be increased when it is combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Vincristine.
DiltiazemThe serum concentration of Vincristine can be increased when it is combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Vincristine.
DipyridamoleThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Vincristine.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Vincristine.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Vincristine.
DoxazosinThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Vincristine can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Vincristine can be increased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Vincristine.
DoxycyclineThe metabolism of Vincristine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Vincristine can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Vincristine can be increased when it is combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Vincristine.
EfavirenzThe serum concentration of Vincristine can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Vincristine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Vincristine.
EltrombopagThe serum concentration of Vincristine can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Vincristine can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Vincristine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Vincristine.
ErgonovineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Vincristine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Vincristine.
ErythromycinThe serum concentration of Vincristine can be increased when it is combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Vincristine.
Eslicarbazepine acetateThe serum concentration of Vincristine can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Vincristine.
EstramustineThe serum concentration of Vincristine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Vincristine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Vincristine can be decreased when it is combined with Estrone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vincristine.
EtoposideThe serum concentration of Vincristine can be increased when it is combined with Etoposide.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Vincristine.
EtravirineThe serum concentration of Vincristine can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vincristine.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Vincristine.
FelodipineThe serum concentration of Vincristine can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.
FexofenadineThe serum concentration of Vincristine can be increased when it is combined with Fexofenadine.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Vincristine.
FidaxomicinThe serum concentration of Vincristine can be increased when it is combined with Fidaxomicin.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Vincristine.
FingolimodVincristine may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe serum concentration of Vincristine can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Vincristine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Vincristine can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vincristine.
FluvoxamineThe serum concentration of Vincristine can be increased when it is combined with Fluvoxamine.
FosamprenavirThe metabolism of Vincristine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Vincristine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Vincristine can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Vincristine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Vincristine can be increased when it is combined with Gefitinib.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Vincristine.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Vincristine.
GenisteinThe serum concentration of Vincristine can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Vincristine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Vincristine can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Vincristine can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Vincristine.
GrepafloxacinThe serum concentration of Vincristine can be increased when it is combined with Grepafloxacin.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Vincristine.
HaloperidolThe serum concentration of Vincristine can be increased when it is combined with Haloperidol.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Vincristine.
HydrocortisoneThe serum concentration of Vincristine can be increased when it is combined with Hydrocortisone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Vincristine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Vincristine.
IdelalisibThe serum concentration of Vincristine can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Vincristine.
ImatinibThe serum concentration of Vincristine can be increased when it is combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Vincristine.
ImipramineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Vincristine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Vincristine.
IndinavirThe serum concentration of Vincristine can be increased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Vincristine.
IndomethacinThe serum concentration of Vincristine can be increased when it is combined with Indomethacin.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Vincristine.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Vincristine.
IsavuconazoniumThe serum concentration of Vincristine can be increased when it is combined with Isavuconazonium.
IsradipineThe metabolism of Vincristine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Vincristine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Vincristine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Vincristine can be increased when it is combined with Ivermectin.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Vincristine.
KetamineThe serum concentration of Vincristine can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Vincristine.
KetoconazoleThe serum concentration of Vincristine can be increased when it is combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Vincristine.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Vincristine.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Vincristine.
LansoprazoleThe serum concentration of Vincristine can be increased when it is combined with Lansoprazole.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Vincristine.
LapatinibThe serum concentration of Vincristine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Vincristine.
LeflunomideThe risk or severity of adverse effects can be increased when Vincristine is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Vincristine.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Vincristine.
LevofloxacinThe serum concentration of Vincristine can be increased when it is combined with Levofloxacin.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Vincristine.
LevothyroxineThe serum concentration of Vincristine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Vincristine can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Vincristine.
LiothyronineThe serum concentration of Vincristine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Vincristine can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Vincristine can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Vincristine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Vincristine can be increased when it is combined with Loperamide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Vincristine.
LopinavirThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Vincristine can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Vincristine can be increased when it is combined with Losartan.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Vincristine.
LovastatinThe serum concentration of Vincristine can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Vincristine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Vincristine can be decreased when it is combined with Lumacaftor.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Vincristine.
MaprotilineThe serum concentration of Vincristine can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Vincristine can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Vincristine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Vincristine can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Vincristine can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Vincristine can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Vincristine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.
MetoprololThe serum concentration of Vincristine can be increased when it is combined with Metoprolol.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Vincristine.
MibefradilThe serum concentration of Vincristine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Vincristine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Vincristine can be increased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Vincristine.
MifepristoneThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Vincristine.
MitomycinThe serum concentration of Vincristine can be increased when it is combined with Mitomycin.
MitomycinThe risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.
MitotaneThe serum concentration of Vincristine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Vincristine can be increased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Vincristine.
ModafinilThe serum concentration of Vincristine can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Vincristine can be increased when it is combined with Morphine.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Vincristine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Vincristine.
NafcillinThe serum concentration of Vincristine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vincristine.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Vincristine.
NaltrexoneThe serum concentration of Vincristine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Vincristine can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.
NefazodoneThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Vincristine can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Vincristine.
NeostigmineThe serum concentration of Vincristine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Vincristine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Vincristine can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Vincristine.
NifedipineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Vincristine.
NilotinibThe serum concentration of Vincristine can be increased when it is combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Vincristine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Vincristine.
NisoldipineThe serum concentration of Vincristine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Vincristine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Vincristine.
NorethisteroneThe serum concentration of Vincristine can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Vincristine.
OlaparibThe metabolism of Vincristine can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Vincristine.
OmeprazoleThe serum concentration of Vincristine can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Vincristine can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Vincristine.
OuabainOuabain may decrease the cardiotoxic activities of Vincristine.
P-NitrophenolThe serum concentration of Vincristine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Vincristine.
PalbociclibThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Vincristine can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Vincristine.
PantoprazoleThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.
PentobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Vincristine can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Vincristine can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.
PimozideThe serum concentration of Vincristine can be increased when it is combined with Pimozide.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Vincristine.
Platelet Activating FactorThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Vincristine.
PonatinibThe serum concentration of Vincristine can be increased when it is combined with Ponatinib.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Vincristine.
PosaconazoleThe serum concentration of Vincristine can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Vincristine can be increased when it is combined with Pravastatin.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Vincristine.
PrazosinThe serum concentration of Vincristine can be increased when it is combined with Prazosin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Vincristine.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.
PrednisoneThe serum concentration of Vincristine can be increased when it is combined with Prednisone.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Vincristine.
PrimidoneThe serum concentration of Vincristine can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Vincristine can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Vincristine can be increased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Vincristine.
PromethazineThe serum concentration of Vincristine can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Vincristine can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Vincristine can be increased when it is combined with Propranolol.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Vincristine.
ProtriptylineThe serum concentration of Vincristine can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vincristine.
QuercetinThe serum concentration of Vincristine can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.
QuinacrineThe serum concentration of Vincristine can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Vincristine can be increased when it is combined with Quinidine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Vincristine.
QuinineThe serum concentration of Vincristine can be increased when it is combined with Quinine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Vincristine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Vincristine is combined with Rabies vaccine.
RanitidineThe serum concentration of Vincristine can be increased when it is combined with Ranitidine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Vincristine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vincristine.
ReboxetineThe serum concentration of Vincristine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Vincristine can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Vincristine can be increased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Vincristine.
RifabutinThe serum concentration of Vincristine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Vincristine can be increased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Vincristine.
RifapentineThe serum concentration of Vincristine can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vincristine.
RilpivirineThe serum concentration of Vincristine can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Vincristine.
RitonavirThe serum concentration of Vincristine can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Vincristine.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Vincristine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Vincristine.
RolapitantThe serum concentration of Vincristine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Vincristine.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Vincristine.
SaquinavirThe serum concentration of Vincristine can be increased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Vincristine.
ScopolamineThe serum concentration of Vincristine can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Vincristine can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Vincristine.
SertralineThe serum concentration of Vincristine can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Vincristine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vincristine.
SiltuximabThe serum concentration of Vincristine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Vincristine can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Vincristine.
SimvastatinThe serum concentration of Vincristine can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vincristine.
SirolimusThe serum concentration of Vincristine can be increased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Vincristine.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Vincristine.
SorafenibThe serum concentration of Vincristine can be increased when it is combined with Sorafenib.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Vincristine.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Vincristine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Vincristine.
SpironolactoneThe serum concentration of Vincristine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Vincristine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Vincristine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Vincristine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Vincristine can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Vincristine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Vincristine can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Vincristine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Vincristine can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Vincristine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Vincristine can be increased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Vincristine.
TamoxifenThe serum concentration of Vincristine can be increased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Vincristine.
Taurocholic AcidThe serum concentration of Vincristine can be increased when it is combined with Taurocholic Acid.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vincristine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Vincristine.
TelaprevirThe serum concentration of Vincristine can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Vincristine.
TelithromycinThe serum concentration of Vincristine can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.
TeniposideTeniposide may increase the neurotoxic activities of Vincristine.
TerazosinThe serum concentration of Vincristine can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Vincristine can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Vincristine can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Vincristine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Vincristine can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Vincristine can be increased when it is combined with Ticagrelor.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Vincristine.
TiclopidineThe metabolism of Vincristine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Vincristine.
TocilizumabThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.
TofacitinibVincristine may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Vincristine can be increased when it is combined with Tolvaptan.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Vincristine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vincristine.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Vincristine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Vincristine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Vincristine.
TrazodoneThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Vincristine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Vincristine can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Vincristine can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Vincristine can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Vincristine.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Vincristine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Vincristine.
VenlafaxineThe serum concentration of Vincristine can be increased when it is combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Vincristine.
VerapamilThe serum concentration of Vincristine can be increased when it is combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Vincristine.
VinblastineThe serum concentration of Vincristine can be increased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Vincristine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Vincristine.
VoriconazoleThe serum concentration of Vincristine can be increased when it is combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Vincristine.
ZimelidineThe serum concentration of Vincristine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Vincristine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB
Uniprot ID:
P07437
Molecular Weight:
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10. [PubMed:19277662 ]
  4. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA4A
Uniprot ID:
P68366
Molecular Weight:
49923.995 Da
References
  1. Yasui M, Koyama N, Koizumi T, Senda-Murata K, Takashima Y, Hayashi M, Sugimoto K, Honma M: Live cell imaging of micronucleus formation and development. Mutat Res. 2010 Oct 13;692(1-2):12-8. doi: 10.1016/j.mrfmmm.2010.07.009. Epub 2010 Aug 5. [PubMed:20691709 ]
  2. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307 ]
  3. Vilpo JA, Koski T, Vilpo LM: Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000 Dec;65(6):370-8. [PubMed:11168494 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73. [PubMed:12490309 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  4. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. [PubMed:9862789 ]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  6. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
  7. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  8. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674 ]
  9. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050 ]
  10. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  11. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644 ]
  2. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726 ]
  3. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490 ]
  4. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Akiyama SI: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol. 1997 Mar;51(3):399-405. [PubMed:9058594 ]
  5. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M: ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol. 1999 Feb;126(3):681-8. [PubMed:10188979 ]
  6. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
  2. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem. 1990 Nov 5;265(31):19279-86. [PubMed:2172249 ]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Molecular Weight:
76062.86 Da
References
  1. Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, Awasthi S: RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol. 2007 Jan;30(1):139-44. [PubMed:17143522 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:28